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Abstract
Maternal and Newborn Outcomes for Women Living with HIV in
Adapted Group Prenatal Care
By Jodi Herron Behr
May 2020
Purpose
The aims of this study were to evaluate group differences between WLWH
who attended individual prenatal care appointments (IC) compared to WLWH who
attended the HIV-adapted CenteringPregnancy® Program (CP-H) for adequacy of
prenatal care utilization, maternal plasma HIV RNA levels, newborn gestational age,
and newborn birth weight.
Methods
A secondary data analysis was used with a total sample size of 233. Univariate
analyses of Chi-square of Independence and Fisher’s Exact test were completed to
identify confounding variables. Univariate analyses for the APNCU index score,
maternal viral load levels, and for newborn gestational age and birth weight. As one
confounding variable was identified, an Analysis of Covariance was also completed for
newborn gestational age and birth weight.
Results
Previous preterm birth was the only confounding variable to be statistically
significant. Significant differences were found for improved outcomes in the CP-H
group for an undetectable viral load (p = .011), newborn gestational age (p = .013), and
newborn birth weight (p = .002). When controlling for previous preterm birth, statistical
significance was found for newborn gestational age (p = .014) and newborn birth weight
iv

(p = .003). The mean and median gestational age and birth weight were higher in the
CP-H group compared to the IC group.
Conclusion
The APNCU index scores for both groups provide updated information for
WLWH. The improvements in undetectable viral load levels for WLWH in CP-H also
provided newer information related for WLWH, while increased newborn gestational age
and increased birth weight for the CP-H group were consistent with improvements seen
in other studies and provided new information regarding group prenatal care for WLWH.
Keywords: CenteringPregnancy®, Women Living with HIV, Newborns
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1
Summary of Study
This study was completed to examine maternal and newborn outcomes for
women living with HIV and their newborns who attended an adapted form of
CenteringPregnancy® program compared to women and their newborns who attended
individual one-on-one prenatal care appointments and did not attend the adapted
CenteringPregnancy® program. The outcomes that were identified were Adequacy of
Prenatal Care Index Score, maternal HIV plasma levels, newborn gestational age, and
newborn birth weight.
This study was conducted as stated in the proposal except for two changes.
The first change was that education level could not be collected as this was not in the
original HIV Perinatal Study database. Second, the maternal HIV plasma levels had to
be changed from an ordinal variable to a dichotomous variable due to laboratory values
of being considered undetectable changed throughout the year.
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Proposal
Specific Aims
Pregnant women living with HIV (WLWH) have increased educational needs
due to the complexity of managing HIV and pregnancy, including the need to
understand the importance of maternal plasma HIV RNA level and its role in
transmission of HIV, an adverse outcome (Centers for Disease Control & Prevention,
2018a; Leyva-Moral et al., 2017). Along with transmission, other adverse outcomes for
newborns born to WLWH include premature birth and low birth weight (Xiao et al.,
2015). Newborn adverse outcomes have been found to be decreased when prenatal care
utilization is found to be considered adequate, a categorical label given to define
prenatal care utilization when prenatal care is begun early and the expected the number
of prenatal care visits per the ACOG guidelines are completed (Cox et al., 2009;
Partridge et al., 2012).
Prenatal care provided one-on-one with an obstetrical provider is an
established intervention with the purpose of providing education and preventing poor
outcomes (American College of Obstetricians & Gynecologists, 2018). Group prenatal
care, including CenteringPregnancy®, which provides a three-prong approach to
prenatal care: health assessment, education, and support, has been associated with
decreased rates of both premature and low birth weight infants for both low and highrisk mothers (Byerly & Haas, 2017; Carter et al., 2016). The CenteringPregnancy®
program was adapted by Judy Levison, MD, MPH and Yvette Peters, APRN, in 2013
for pregnant WLWH by including education related to HIV medications, management
of the disease, and the disease’s potential effect on the newborn (Hickerson et al.,
2019; Rising & Quimby, 2017). Outcomes of the HIV-adapted CenteringPregnancy®
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program comparing group prenatal care and traditional prenatal care have not yet been
evaluated. The critical need is to determine the best model of care delivery for
WLWH. The long-term goal will be to determine if adapting the
CenteringPregnancy® program will be beneficial to other high-risk groups. The
overall objective of this study is to evaluate the effects of the increased HIV education
included in the HIV-adapted CenteringPregnancy® program for WLWH and their
newborns. The central hypothesis is that WLWH who attend the HIV-adapted
CenteringPregnancy program® will have improved outcomes for both the mother and
the newborn. The rationale for this project is that once outcomes are known, the
program may be implemented in other cities and/or countries to determine
generalizability. To obtain the overall objective, the following three specific aims will
be pursued:
1. To evaluate adequacy of prenatal care for WLWH who attended the HIVadapted CenteringPregnancy® program prenatal care appointments. The hypothesis is
that WLWH who attend the HIV-adapted CenteringPregnancy® program will have
increased prenatal care adequacy compared to pregnant WLWH who attend traditional
prenatal care.
2. To evaluate maternal plasma HIV RNA levels for WLWH who attend the
HlV- adapted CenteringPregnancy® program. The hypothesis is that WLWH who
attend the HIV-adapted CenteringPregnancy® program will have a lower plasma HIV
RNA level prior to delivery compared to WLWH who attend traditional prenatal care
appointments.
3. To evaluate the gestational age and birth weight of newborns born to WLWH
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who participate in the HIV-adapted CenteringPregnancy® program. The hypothesis is
that newborns born to WLWH who attend the HIV-adapted CenteringPregnancy®
program will have increased gestational ages and birth weights compared to WLWH
who attend traditional prenatal care appointments.
The expected outcomes of these aims are to identify improvements in the
educational and group components of prenatal care for WLWH and their newborns.
With WLWH attending the HIV-adapted CenteringPregnancy® program and receiving
increased education related to HIV in a supportive group setting, WLWH will be able to
engage in promoting their own health during pregnancy for themselves and for their
newborn.
Significance
With the success of antiretroviral therapy (ART), HIV is now considered a
chronic illness (Deeks et al., 2013). There are an estimated 255,900 WLWH in the
United States (US) of which approximately 8,500 will give birth each year (Centers for
Disease Control & Prevention [CDC], 2019b). Adverse outcomes have been found to
affect newborns born to WLWH, including premature birth and low birth weight
(Macdonald et al., 2015).
As women manage both their pregnancy and HIV, their focus is on preventing
HIV transmission to their newborn and having a healthy outcome for both themselves
and their newborn. To do this, WLWH must manage both their disease and pregnancy
at the same time (Craft et al., 2007). Management of both, along with decreasing the
fear of transmission is facilitated by comprehensive education. With adherence to
medications, the risk of mother to child transmission (MCT) is approximately 1-2%
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(Centers for Disease Control & Prevention [CDC], 2019). While the risk of
transmission is zero if a woman is virally suppressed from conception to delivery
(Mandelbrot et al., 2015).
Prenatal care is a long-standing and widely used public health intervention for
the prevention of pregnancy-induced hypertension in US and other developed
countries. Prenatal care is also important as it identifies ongoing risk during the
pregnancy and includes assessment of medical, psychosocial, nutritional, cultural, and
educational needs of the mother (American Academy of Pediatrics Committee on Fetus
and Newborn & The American College of Obstetricians and Gynecologists Committee
on Obstetric Practice and Gynecologists [(AAP Committee on Fetus & Newborn &
ACOG Committee on Obstetric Practice)], 2012). Prenatal care guidelines set forth by
ACOG include appointments with a healthcare provider every four weeks for the first
28 weeks, every two weeks until 36 weeks, and then weekly until delivery. However,
this schedule is modifiable based upon findings at each assessment. These
appointments allow the healthcare provider to provide ongoing assessments of the
mother and fetus, complete health screenings, provide education, and detect any
medical or psychosocial complications that the mother may be experiencing (Alexander
& Kotelchuk, 2001).
Even with the suggested visits, the actual utilization of prenatal care is needed
to determine the care that is being provided. Utilization has been defined as adequate if
care is initiated early in the pregnancy and visits are fulfilled according to the ACOG
standards (Partridge et al., 2012). To quantify prenatal care related to the amount of care
provided, different index scores may be used, including the Adequacy of Prenatal Care
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Utilization Index (Kotelchuck, 1994a).
The delivery of prenatal care has been traditionally a one-on-one
appointment with a healthcare provider. However, since the 1990s when group
prenatal care was introduced, group prenatal care demonstrated improvement in
patient education and satisfaction with no detrimental effects to the mother or the
fetus. Group care has recently been endorsed by AGOG (2018). Unlike traditional
one-on-one prenatal care that was not studied utilizing strong research rigor, group
prenatal care models have continued to undergo scientific scrutiny to determine its
effects on outcomes for both low and high- risk mothers during the antenatal period
of pregnancy (Benediktsson et al., 2013, Chae, et al., 2017; Cunningham et al.,
2019; Earnshaw et al., 2016; Heberliein et al., 2016, Ickovics et al., 2003, Ickovics
et al., 2007, Ickovics et al., 2016, Picklesimer et al., 2012, Zorrilla et al., 2017).
The structure of group prenatal care consists of women with similar due dates
coming together in a group setting to learn about and discuss pregnancy, newborn, and
post-partum topics. Women receive individual care for their physical assessment by a
healthcare provider and they actively participate in collecting their own healthcare data
such as their weight and blood pressure. In the group session led by healthcare
providers or social workers, different topics are discussed, and group members ask
questions and are encouraged to share information (Rising, Kennedy, & Klima, 2004).
One formalized group prenatal care program is the CenteringPregnancy®
program offered through the CenteringHealthcare Institute. CenteringPregnancy® was
started by Sharon Rising, a certified nurse midwife, in 1995 and as of March 2019,
CenteringPregnancy® is now practiced at 424 sites across the US
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(CenteringHealthcare Institute, 2019). The CenteringPregnancy® program follows a
systematic program on specific education topics. Yet, the CenteringPregnancy®
program has also approved the adding of specific topics for high risk groups including
WLWH. The programing for WLWH was adapted by Judy Levison, MD, and Yvette
Peters, APRN, to not only include the CenteringPregnancy® topics, but to also include
information related to HIV disease during and after pregnancy and newborn concerns
(Hickerson et al., 2019).
Group prenatal care has shown improvements in the percentages of premature
births and birth weights in low risk mothers. Improvement in newborn birth weights
have also been noted in high-risk mothers such as those with gestational diabetes who
participated in group prenatal care (Cunningham et al., 2019; Ickovics et al., 2003,
Ickovics et al., 2007, Ickovics et al, 2016; Mazzoni et al., 2015; Schellinger et al.,
2016; Pickelesimer et al., 2012; Schellinger et al., 2016; Zorrilla et al., 2017). Pregnant
women reported it allowed them time with the healthcare provider for a physical
assessment but also gave them increased time for education and support through the
group format (Benediktsson et al., 2013, Chae et al., 2017; Cunningham et al., 2019;
Earnshaw et al., 2016; Heberliein et al., 2016, Ickovics et al., 2003, Ickovics et al.,
2007, Ickovics et al., 2016, Picklesimer et al., 2012, Zorrilla et al., 2017).
The gap in knowledge lies in determining if there are different outcomes related
to WLWH and their newborns who attend the HIV-adapted CenteringPregnancy®
program compared to WLWH who completed traditional one-on-one prenatal care prior
to group care being offered. This information is essential in understanding the impact
of the HIV- adapted CenteringPregnancy® program for WLWH and their newborns. It
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is yet to be determined if the HIV-adapted CenteringPregnancy® program has a
positive effect on program indicators and clinical outcomes: (1) adequacy of prenatal
care, (2) maternal HIV plasma viral load, and (3) newborn’s gestational age and (4)
their birth weight.
The significance of this research will be to evaluate two aspects of the HIVadapted CenteringPregnancy® program, adequacy of prenatal care and HIV viral
load, along with evaluating two outcomes, the newborn’s gestational age and birth
weight. The contribution of this research is to provide new information to maternalchild healthcare providers regarding the HIV-adapted CenteringPregnancy®
program for WLWH and its impact on newborns’ gestational ages and birth weights.
The theoretical framework that will guide this research is the
CenteringPregnancy Conceptual Model (Manat & Dodgson, 2011). This model is
guided by the feminist, midwifery, social cognitive, and adult learning theories. These
theories support the relationship-based care, active learning, and self-efficacy
components of the CenteringPregnancy® program. Self-efficacy includes how people
feel, motivate themselves, and act to accomplish a specific goal. Guided by these
theories, the CenteringPregancy model identifies the group process and the purposeful
self-reflection as key components of the process which propels women to their optimum
self which will lead to a healthy pregnancy and positive birth outcomes (Manant &
Dodgson, 2011).
Adequacy of prenatal care. Adequacy of prenatal care has been measured by
several utilization indexes, including the Adequacy of Prenatal Care Utilization Index
(APNCU). The APNCU index uses the number of prenatal care visits and the timing of
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the initiation of prenatal care into consideration to determine a status of adequacy. The
index is a summation score based upon the gestational month prenatal care began and the
ratio of observed versus expected visits and the timing of the initiation of prenatal care.
The calculated index is categorized as either adequate plus, adequate, intermediate, or
inadequate (Kotelchuck, 1994a). WLWH have been shown to have inadequate prenatal
care (Ng et al., 2015) and newborns born to WLWH who had inadequate prenatal care
had increased odds of having a low birth weight or being born premature compared to
newborns born to women who did have HIV (Turner et al., 1996).
Plasma HIV RNA levels. For WLWH, the goal of ART is to obtain an
undetectable maternal plasma HIV RNA level as this helps decrease the risk of perinatal
transmission of HIV to the newborn (CDC, 2019a; U.S. Department of Health &
Human Services, 2018). Medication adherence to ART is known to have the largest
impact on viral load suppression in pregnant women (Zahedi-Spung, Young, Haddad,
& Badell, 2018). Therefore, WLWH must understand the relationship among
medication adherence, maternal plasma HIV RNA level, and decreased transmission to
the newborn. Medication adherence among pregnant WLWH has been reported at
approximately 75% (Bardeguez et al., 2008; Mellins et al., 2008; Zahedi-Spung et al.,
2018). Combination interventions that include education have been noted to be effective
at increasing ART adherence compliance and a lack of education has been identified as
a barrier to medication adherence during pregnancy which can lead to increased plasma
HIV RNA levels (Chaiyachati et al., 2014).
Newborn gestational age and birth weight. The percentage of premature birth
in the US in 2017 was 9.9% of all live births while the percentage of births considered
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low birth weight was 8.3% in the US. A newborn is considered premature if it is born
before 37 weeks gestation. Low birth weight is defined as a birth weight of less than 2.5
kilograms or 5 pounds, 5 ounces (Centers for Disease Control & Prevention, 2017).
Some of the maternal risk factors that can lead to either premature birth or low birth
weight are previous preterm birth, mother who smoked during pregnancy or consumed
other substances such as marijuana and/or alcohol, and if the mother had other infections
during the pregnancy (Bowers, 2014). Newborns born to WLWH are at twice the risk of
being premature and/or low birth weight compared to newborns who are not exposed to
the virus (Xiao et al., 2015).
Preliminary Studies
No preliminary studies have been conducted by this researcher. What is known from
the literature follows:
Adequacy of Prenatal Care
Aim 1: To evaluate adequacy of prenatal care for WLWH who attended the HIVadapted CenteringPregnancy® program prenatal care appointments.
During the 1990s WLWH were found to have inadequate prenatal care despite
needing to initiate zidovudine, the primary drug prescribed to WLWH to decrease
maternal-child transmission (Lanksy et al., 1999; Turner et al., 1996). WLWH have
been shown to struggle to initiate and engage in prenatal care during the course of their
pregnancy. More recently, 43.3% of WLWH compared to 36.1% not living with HIV
received inadequate prenatal care (Ng et al., 2015). Studies involving the use of group
prenatal care have shown improvement in improving the adequacy of prenatal care
utilization. In one randomized control trial, 26.6% of adolescents who participate in
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CenteringPregnancy® had inadequate prenatal care based upon the APNCU index
compared to 33% of adolescents having inadequate prenatal care in a traditional oneon- one care (Ickovics et al., 2007). Another improvement in prenatal care utilization
was found with group care with Latina women as those who attended
CenteringPregnancy® had higher prenatal care adequacy ratios compared to Latina
women in traditional one- on-one care (Tandon et al, 2013).
Three risk factors that have been identified for inadequate prenatal care
are the age, race, and education level of the mother (Patridge et al., 2012; Lambert,
Mugaver, Najjar, Enah, & Guthrie, 2018; Xaverius et al., 2016). In 2016,
approximately 27% of women under 20 years of age had inadequate prenatal care
along with approximately 20% of mothers between the ages of 20 and 24 (U.S.
Department of Health & Human Services, 2018). The association with mothers who
were younger with less education has been identified with receiving less adequate
prenatal care (Patridge et al., 2012; Xaverius et al., 2016). Black women have also
been identified as having less adequate prenatal care compared to other races
(Lambert et al., 2018).
Plasma HIV RNA Levels
Aim 2: To evaluate plasma HIV RNA levels for WLWH who attend the HIV-adapted
CenteringPregnancy® program.
An undetectable HIV RNA level in pregnant WLWH is the goal to decrease the
risk of maternal-child transmission of HIV (Bardeguez et al., 2008; Patel et al., 2018).
An undetectable viral load is achieved by taking daily medication. Understanding the
relationship of daily medication use and its effect on the maternal HIV plasma RNA
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level on the newborn is a key piece of education in prenatal care for pregnant WLWH
(The American College of Obstetricians & Gynecologists, 2017). Despite the
importance of medication adherence, current studies have shown that with traditional
prenatal care, medication adherence is considered at a non-compliant rate and therefore
puts the newborn at risk for maternal child transmission (Zahedi-Spung et al., 2018).
Maternal age and race have been identified as factors for having and increased HIV
Plasma RNA level. Women who are younger and who are Black have been shown to
have increased plasma HIV RNA levels (Patel et al., 2018).
Newborn Gestational Age and Birth Weight
Aim 3: To evaluate the gestational age and birth weight of newborns born to WLWH
who participate in the HIV-adapted CenteringPregnancy® program.
Newborns of WLWH are at risk for decreased gestational age and birth weight.
Despite overall decreases in preterm birth and decreased birth weight among all
newborns in the US, the percentage of preterm births and low birth weight newborns
born to WLWH are still greater compared to women who do not have HIV (Macdonald
et al., 2012). In the US, race and maternal substance abuse were factors for both preterm
delivery and low birth weight newborns born to WLWH (Schulte, Dominguez, Sukalac,
Bohannon, & Fowler, 2006).
The contribution of this research study will be to identify the positive effects of
the CenteringPregnancy® group prenatal care model for WLWH and their newborns.
It will identify the role of CenteringPregnancy® has on prenatal care adequacy, HIV
RNA plasma levels, and the newborn’s gestational age and birth weight. WLWH are
an increasing population as these women are living longer lives and desiring to
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become pregnant. With the advancements in ART, pregnancy outcomes can be
positive with effective education and support. The group aspect of
CenteringPregnancy® can also provide the education and support needed by WLWH.
Currently prenatal care one-on-one appointments are the model of care for WLWH.
This research will help identify if the CenteringPregnancy® program model can
provide WLWH a group format for education and care that will enhance their
understanding of the importance of medication adherence and provide overall
improved newborn outcomes for an at-risk population.
Innovation
The CenteringPregnancy® program is an innovate alternative care model to
the status quo traditional care model for pregnant WLWH. With pregnant WLWH
having increased education needs, a group prenatal care setting specific to WLWH
can provide the healthcare they need in a supportive setting. As this is a new model
of care for WLWH, outcomes need to be evaluated.
Approach
Design
The proposed study will be a secondary data analysis from the Baylor
College of Medicine HIV Perinatal Study (IRB Number 14-01-0733). This sample
will include WLWH who sought care at the Harris Health/Baylor College of
Medicine Northwest Obstetrical & Gynecology Clinic in Houston, Texas. This
investigator has been added to the HIV Perinatal Study and has been granted access
to the electronic database involved in this study. The dates of inquiry for this study
will include data extracted from Harris Health patients’ charts from 2006-2018 and
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entered into the Baylor College of Medicine Clinical Trial Management System
(BCM CTMS). The groups being compared will be WLWH who attended
traditional prenatal care and their newborns (control) and WLWH who attended the
HIV-adapted CenteringPregnancy® program prenatal care program and
their newborns (intervention). The control group will be WLWH who attended
traditional one-on-one prenatal care from 2006-2012 and the intervention group will
be the WLWH who attended the HIV-adapted CenteringPregnancy® program from
2013-2018.
In 2013, HIV-related topics were added to the traditional
CenteringPregnancy® program. This program of care became known as the HIVadapted CenteringPregnancy® curriculum. The following HIV topics and related
speakers were added to enhance the traditional prenatal care topics (see Table 1):
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Table 1
Schedule for HIV Education Topics
Session (weeks of
pregnancy)

HIV topic

1 (Weeks 12-16)

Coping with HIV diagnosis; what is was like at the
time of diagnosis; psychiatry speaker

2 (Weeks 16-20)

HIV basics; HIV & pregnancy

3 (Weeks 20-24)

Retention in care; HIV medication
adherence/breastfeeding; primary care speaker

4 (Weeks 24-28)

HIV and birth control

5 (Weeks 26-30)

Birth facility; breastfeeding

6 (Weeks 28-32)

HIV and medication adherence; disclosure of HIV

7 (Weeks 30-32)

Pediatric speaker

8 (Weeks 32-36)

Caring for baby (no new HIV topic)

9 (Weeks 34-38)

Identifying a primary care provider for self and
baby

10 (Weeks 36-40)

How to obtain medications, serodiscordance- PrEP;
retention in care –Mentors

The population of interest for this study will be pregnant WLWH and their
newborns. The sample will be drawn from WLWH who were provided prenatal
care at the Harris Health Northwest Health Center and their newborns. The
Northwest Harris Health Center and is part of Harris Health System and is staffed
by Baylor College of Medicine physicians. The investigator will first separate
patients into two groups, WLWH who attended traditional prenatal care from 2006
to 2012 and their newborns and WLWH who attended the HIV-adapted
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CenteringPregnancy® program from 2013 –2018 and their newborns. These years
are included as they are the years during which only traditional one-one-one care
was provided and years when the HIV-adapted CenteringPregnancy® program was
implemented. A convenience sample will be used. Inclusion criteria will include
WLWH who had a single pregnancy, 18 years of age and older, started prenatal
care at Harris Health by gestational week 30, and the pregnancy resulting in a live
birth. Exclusion criteria includes WLWH with a multiple gestation pregnancy,
WLWH less than 18 years of age, any newborn with known congenital anomalies,
or if the pregnancy resulted in a fetal demise or miscarriage. An a priori sample size
was determined using G Power 3.1.9.2 statistical software. The a priori power will
be at 0.80 and an a priori alpha level will be set at .05. The effect size for the
logistic regression will be when the odds ratio is 2.88. For the linear regression
model, the effect size will be .034. For this study, a sample size of 225 subjects’
records will be needed.
Procedure for Data Collection
By being part of the Baylor HIV Perinatal study, the principal investigator
already has been approved for access to information to the Baylor College of Medicine
Clinical Trials Database. This database currently holds the information for the HIV
Perinatal Study (BCM CTMS HIV Perinatal Study database. Baylor College of
Medicine monitors the Clinical Trial Management System (BCM CTMS), as it is a
password-protected system. See Appendix A for data management and codebook. The
information entered into the SPSS workbook will be validated by reviewing every 10th
entry into the SPSS workbook. The SPSS and SAS workbook will be saved on a
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secure Cizik School of Nursing’s password-protected online database. Informed
consent will not be garnered as this is a retrospective chart review. Data will be
extracted and entered into SPSS v. 25 by this investigator and will include
demographics of age and race and exclusion variables of multiple pregnancy and fetal
demise will be noted and known factors that also contribute to preterm birth of
infections, smoking status, and previous preterm birth. For each of the aims the
following variables will be collected:
Aim 1
Data points to calculate the APNCU Index will include the following:
1. Number of prenatal care appointments attended at Harris Health
2. The gestational month prenatal care was initiated
3. Newborn gestational age in weeks
Aim 2
Data for the outcome variable for Aim 2 will also be extracted from the BCM CTMS
HIV Perinatal Study database. The last viral load recorded prior to date of delivery
will be used. The levels of the maternal HIV plasma RNA levels will be categorized
as less than 20, 20-999, and 1,000 and greater. A plasma level is considered
undetectable at less than 20.
Aim 3
Data for the outcome variable for Aim 3 will be found in the BCM CTMS Perinatal
HIV Study database will include the newborn’s gestational age and the newborn’s
birth weight. The newborn’s gestational age will be provided in weeks and days. To
include the days in SPSS, the gestational age will need to include the weeks of
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gestation and the decimal interpretation of the number of days divided by 7. See
Table 2 for variables.
Table 2
Data Collection Table
Variable

Variable Type

Age

Continuous

Race

Number of years
Categorical

Maternal Educational Level

Caucasian
Black
Hispanic
Other
Continuous

APNCU Index (Adequacy Index)

Grade level achievement
Ordinal

Plasma HIV RNA levels

1 = inadequate
2 = intermediate
3 = adequate
4 = adequate plus
Ordinal

Newborn gestational age

0 = less than 20
1 = 20 to 999
2 = 1,000 or greater
Continuous

Newborn birth weight

Weeks of gestation
Continuous
Kilograms

Measurements
There will be no instruments used in this study. All the variables are
located in the BCM CTMS and were collected for the Perinatal HIV Study.
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Data Analysis Plan
Descriptive statistics for the demographic variables of age and race
will be completed for each group. All variables will be assessed for normal
distribution.
To calculate the APNCU Index Score, the below three variables will be transferred
from SPSS into SAS for calculation. The APNCU Index Score program was written
in SAS by the original APNCU Index Score author, Milton Kotelchuch, PhD.
1. The number of prenatal care appointments will be labeled as
NPCVBC (number of prenatal care visits).
2. The gestational month prenatal care was initiated will be labeled
MPCBBC (month prenatal care began). This will be calculated by
taking the estimated weeks into the Harris Health program and
dividing by 4 to determine the month.
3. The gestational age will be labeled as GAGEBC (gestational age in weeks).
An index score will be calculated using the SAS Computational program
developed by Milton Kotelchuck, PhD, MPH (1994b). The index score is a
summative score that includes the month of gestation that prenatal care began, and
the ratio of observed visits compared to expected visits. The Utilization Index score
can be categorized into 4 groups:
1. Inadequate: Prenatal care began after the 4th month or less than
50% of recommended visits occurred.
2. Intermediate: Prenatal care began by the 4th month and 50-79% of
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recommended visits occurred.
3. Adequate: Prenatal care began by the 4th month and 80-109% of
recommended visits occurred.
4. Adequate Plus: Prenatal care began by the 4th month and 110% or
more of recommended visits occurred.
Once calculated, the APNCU index scores will be transferred back to SPSS
for the logistic regression analysis. To assess for statistical differences
between the two groups (traditional prenatal care and HIV-adapted
CenteringPregnancy®) for the following dependent variables, these
statistical tests will be calculated (See Table 3).
Table 3
Dependent Variables & Corresponding Statistical Test
Dependent Variable

Statistical Test

Age

t-test

Race

Chi-Square

Maternal Education Level

t-test

Other Infections

Chi-Square

Smoking Status

Chi-Square

Other substance abuse

Chi-Square

Preeclampsia diagnosis

Chi-Square

Previous preterm birth

Chi-Square
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If a statistical difference is found between the group means of each group of
any of the above variables, these will then be included in a multivariate analysis. For
the dependent variable Adequacy of Pregnancy Index Score and for the plasma HIV
RNA level, a logistic regression will be completed. For gestational age and low birth
weight, a linear regression model will be completed. If no statistical difference is
found for the above variables between the two groups, then univariate analyses will
be completed (See Table 4).
Table 4
Dependent Variable & Corresponding Statistical Test for Univariate Analyses
Dependent Variable

Statistical Test

Adequacy of prenatal care index score

Wilcoxon-Mann-Whitney Test

Maternal plasma HIV RNA level

Wilcoxon-Mann-Whitney Test

Newborn gestational age

t-test

Newborn birth weight

t-test

Potential Limitations & Risk to Subjects
There are several limitations of this study that may occur. The first limitation
potentially will be a lack of data due to the study being a secondary data analysis. If
data is missing, a smaller sample size might be obtained than what is proposed by the
power analysis. Another limitation could be that since data extraction from the Harris
Health patients’ charts was completed by several data collectors, despite having a
guide sheet, the data may have been found in different areas of the chart leading to
different interpretations by the data collectors. A third limitation is that care was not
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simultaneous for each group. Finally, the care providers could be different as the
years included in this study are over a 9-year period. As this is a secondary data
analysis, the risk to subjects will be minimal. The information will be de-identified
once it is removed from the BCM CTMS.
Human Subject Protection
As this will be a secondary data analysis, no informed consent will be
obtained. Once a subject is included in the study, the data collected will be deidentified. The original HIV Perinatal Study was approved by the Baylor College of
Medicine Institutional Review Board (see Attachment 1). This secondary data
analysis of the HIV Perinatal Study data was approved by the Principal Investigator,
Judy Levison, MD. The letter of support from Dr. Levison is attached as Attachment
2.
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Maternal and Newborn Outcomes for Women Living with
HIV in Adapted Group Prenatal Care
Of the approximately 255,900 women living with HIV (WLWH) in the
United States (US), approximately 8,500 give birth each year. With the success of
women’s adherence to prescribed combined antiretroviral therapy (cART) during
pregnancy, the risk of mother to baby transmission is approximately 1-2% (Centers
for Disease Control and Prevention, 2019b; Leyva-Moral et al., 2017), while the
risk decreases to 0% if a WLWH is virally suppressed from conception to delivery
(Mandelbrot, 2015). Despite the decreased risk of viral transmission, newborns
born to WLWH have been identified as being at risk for both prematurity and low
birth weight (Xia et al., 2015). As with any pregnancy, WLWH desire healthy
outcomes for both themselves and their newborns. To accomplish a healthy
outcome, they must both successfully manage their pregnancy and HIV infection
(Craft, Delany, Bautista, & Serovich, 2007).
Management of the pregnancy and HIV infection is accomplished through
prenatal care and ongoing self-management between prenatal care appointments.
During one-on-one visits established as the standard of prenatal care by The
American College of Obstetricians and Gynecologists (ACOG) (American
Academy of Pediatrics (AAP) Committee on Fetus & Newborn & ACOG
Committee on Obstetric Practice, 2012), the health care provider evaluates mothers
and their fetuses through ongoing assessments, health screenings, and through
detection of any further medical and/or psychosocial complication that may occur
during pregnancy. Education also is provided during these appointments regarding
pregnancy, birth, and issues related to HIV, such as the importance of medication
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adherence (ACOG, 2017).
Changes related to traditional prenatal care were introduced in the 1990s
through group prenatal care. One formalized group prenatal care program is the
CenteringPregnancy® program, developed in 1995 by Sharon Rising, a certified
nurse midwife, and is now offered through the CenteringHealthcare Institute
(CenteringHealthcare Institute, 2019; Rising et al., 2004; Rising & Quimby, 2017).
With a group model of care, pregnant women receive one-on-one assessments
along with education and support in a group setting. The program allows other
women to not only learn from the health care provider but also from each other
(Chae et al., 2017; Earnshaw et al., 2016; Heberliein et al., 2016). According to
Carter et al. (2016), observational studies have shown improved newborn outcomes
for newborns born to mothers who attended group prenatal care.
The purpose of this study was to assess outcomes for both pregnant women
living with HIV and their newborns through a retrospective data review. The four
aims and the hypotheses for this study were: (1) to evaluate the adequacy of
prenatal care utilization for WLWH who attended the HIV-adapted
CenteringPregnancy® program (CP-H) program compared to WLWH who
attended individual one-on-one care (IC). The hypothesis was that WLWH who
attended CP-H would have increased prenatal care adequacy utilization compared
to pregnant WLWH who attend IC; (2) to evaluate maternal plasma HIV RNA
levels for WLWH who attended CP-H compared to WLWH who attended IC. The
hypothesis was that WLWH who attended CP-H would have a lower plasma HIV
RNA levels prior to delivery compared to WLWH who attended IC; (3) to evaluate
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the gestational age of newborns born to WLWH who participate in CP-H compared
to gestational age of newborns born to WLWH who participated in IC. The
hypothesis was that newborns born to WLWH who attended CP-H will have
increased gestational ages compared to newborns born to WLWH who attended
IC; and (4) to evaluate the birth weight of newborns born to WLWH who
participate in the CP-H compared to newborns born to WLWH who participated in
IC. The hypothesis was that newborns born to WLWH who attend the CP-H will
have increased birth weights compared to newborns born to WLWH who attended
IC.
Background
The primary goal of every pregnancy is for the mother and newborn to be
healthy. This goal can be more challenging for pregnant women living with a
chronic illness, such as HIV, as they must take cART, the standard of care
medications, daily to avoid mother- to-child transmission (Deeks et al., 2013). With
a low to non-existence mother-to-child transmission of HIV and the desire of
WLWH to have children, the pregnancy rate among WLWH in the US has
increased (Rahangdale et al., 2014). However, despite the desires to have children,
it has been shown that WLWH may not have the appropriate level of awareness and
understanding regarding management of HIV during pregnancy to achieve healthy
outcomes. Therefore, education of WLWH pre-conception and intra- pregnancy is
of the utmost importance to help them understand the knowledge needed to manage
their disease and pregnancy (Finocchario-Kessler et al., 2010).
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Prenatal Care
Prenatal care is a long-standing and widely used public health intervention
for the prevention of pregnancy-induced hypertension in the US and other
developed countries. Prenatal care also is important to identify ongoing risk during
the pregnancy and includes assessment of medical, psychosocial, nutritional,
cultural, and educational needs of the mother (AAP Committee on Fetus &
Newborn & ACOG Committee on Obstetric Practice, 2012). Prenatal care
guidelines set forth by ACOG include appointments with a healthcare provider
every four weeks for the first 28 weeks, every two weeks until 36 weeks, and then
weekly until delivery. However, this schedule is modifiable based upon findings at
each assessment. These appointments allow the healthcare provider to provide
ongoing assessments of the mother and fetus, complete health screenings, provide
education, and detect any medical or psychosocial complications that the mother
may be experiencing (AAP Committee on Fetus and Newborn & The ACOG
Committee on Obstetric Practice and Gynecologists, 2012).
Group Prenatal Care
The delivery of prenatal care has been historically an individual one-on-one
appointment with a healthcare provider. However, since the 1990s when group
prenatal care was introduced, group prenatal care demonstrated improvement in
patient education and satisfaction with no detrimental effects to the mother or the
fetus. Group care has recently been endorsed by ACOG (2018). Unlike individual
prenatal care that was instituted as a guideline without strong research rigor, group
prenatal care models have continued to undergo scientific scrutiny to determine its
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effects on outcomes for both low and high-risk mothers during the antenatal period
of pregnancy. Studies which support group prenatal care include those by
Benediktsson et al. (2013), Chae et al. (2017), Cunningham et al. (2019), Earnshaw
et al. (2016), Heberliein et al. (2016), Ickovics et al. (2003), Ickovics et al. (2007),
Ickovics et al. (2016), Picklesimer et al. (2012), and Zorrilla et al (2017).
The structure of group prenatal care consists of women with similar due
dates coming together in a group setting to learn about and discuss pregnancy,
newborn, and post-partum topics. In the group session led by healthcare providers
or social workers, these topics are discussed, and group members ask questions and
are encouraged to share information (Rising et al., 2004; Rising & Quimby, 2017).
Women also receive
individual care for their physical assessment by a healthcare provider and they
actively participate in collecting their own healthcare data such as their weight
and blood pressure. By participating in CenteringPregnancy®, women have
increased time for education and support along with individual time with a health
care provider (ACOG,
2018).
As of December 2019, CenteringPregnancy® is practiced at over 500 sites
across the US (CenteringHealthcare Institute, 2019). The CenteringPregnancy®
program follows a systematic program on specific education topics. Yet, the
CenteringPregnancy® program also has approved the adding of specific topics for
high risk groups including WLWH. The CenteringPregnancy® programing for
WLWH was developed to not only include the CenteringPregnancy® topics, but to
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also include information related to HIV disease during and after pregnancy, and
newborn concerns. These topics included: coping with HIV, HIV and pregnancy,
importance of medication and retention in care, disclosure of HIV, breastfeeding
specifics to WLWH, and birth control concerns for WLWH. These topics are in
addition to the traditional prenatal care topic of each of the 10 sessions. One recent
study conducted by Hickerson et al. (2019) with WLWH who participated in the
program found improvements in social support and decreased depression scores.
In observational studies, group prenatal care has shown improved birth
weights and a decrease in premature births in low risk mothers (Carter et al., 2016).
Improvement in newborn birth weights also have been noted in high-risk mothers
such as those with gestational diabetes who participated in group prenatal care
(Byerly & Haas, 2017; Mazzoni et al. 2015).
Adequacy of Prenatal Care
Utilization of prenatal care can be used to quantify the care that is being
provided to women during the prenatal period. Utilization has been defined as
adequate if care is initiated early in the pregnancy and visits are fulfilled according
to ACOG standards (Partridge et al., 2012). To quantify prenatal care, different
utilization scores have been developed, such as the Kotelchuck Index, the RGINDEX, and the Adequacy of Prenatal Care Utilization (APNCU) Index
(Alexander & Kotelchuk, 1996; Alexander & Kotelchuck, 2001; Kotelchuck,
1994a; Heaman et al., 2008). The APNCU index score is a multi-dimensional score
that takes into consideration when prenatal began based upon the month of
initiation and the actual number of visits in a woman’s time in prenatal care based
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upon the delivery date. WLWH have struggled with the initiation and engagement
of traditional prenatal care. During the 1990s, women were found to have
inadequate prenatal care despite needing to initiate zidovudine, the primary drug
prescribed to WLWH at the time (Lanksy et al., 1999). This pattern of lower
prenatal engagement also was found by Turner et al (1996) among pregnant
WLWH.
Maternal Viral Load Levels
For WLWH, the goal of cART is to obtain an undetectable maternal HIV
RNA levels, also known as viral load levels, to decrease the risk of perinatal
transmission of HIV to the newborn (CDC, 2019b; US Department of Health &
Human Services, 2018). Medication adherence with cART is known to have the
largest impact on viral load suppression in pregnant women (Zahedi-Spung et al.,
2018). One way to achieve viral load suppression is to take cART daily. Despite its
utmost importance, cART adherence among pregnant WLWH has been reported at
approximately 75% which is considered to be in the non-compliant range (Bardeguez
et al., 2008; Zahedi-Spung et al., 2018). Reasons that WLWH give for this
noncompliance include “forgetting to take medication daily”, concern that the cART
will harm the newborn instead of helping him/her, lack of transportation to refill
medication, and lack of general knowledge regarding mother-to- child transmission
(Hodgson et al., 2014). Interventions that include education along with psychosocial
support and/or other types of reminder systems have been noted to be effective at
increasing cART adherence (Bardeguez et al., 2008; Chaiyachati et al., 2014).
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Birth Outcomes for WLWH
With the improvements in preventing of mother-to-child transmission,
attention has turned to other newborn outcomes. Two significant factors noted to
affect newborns born to WLWH are prematurity and low birth weight (Macdonald
et al., 2015; Xiao et al, 2015). The overall percentage of premature birth (birth
before 37 weeks gestation) in the US in 2018 was 10.0% of all live births (March of
Dimes, 2019). While 8.3% of newborns born in the US in 2017 were defined as low
birth weight (CDC, 2019a). According to Xiao et al. (2015), newborns born to
WLWH are estimated to be at a two- fold risk increase of being either premature or
low birth weight, yet it is not associated with cART. Low birth weight is defined as
a birth weight of less than 2.5 kilograms or 5 pounds, 5 ounces (AAP Committee on
Fetus & Newborn & ACOG Committee on Obstetric Practice, 2012). Researchers
continue to examine reasons for prematurity and low birth weight outcomes for
newborns born to WLWH.
Social factors such as age and race/ethnicity have been identified as risk
factors for decreased adequacy of prenatal care, increased maternal viral load levels,
premature birth, and low birth weight for newborns (Lambert et al., 2018; Patel et
al., 2018; Schulte et al., 2006; Xaverius et al., 2016). Behavioral risk factors such as
smoking and substance abuse often are found in this population and have been
shown to have an impact on adequacy of prenatal care, maternal viral load levels
and the newborn’s gestational age and birth weight (Chaiyachati et al., 2014;
Lambert et al., 2018; Patridge et al., 2012; Xaverius et al., 2016;). Along with
behavioral risk factors, other medical diagnoses such as preeclampsia and previous
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preterm birth could also affect a newborn’s outcomes (Yang et al., 2016).
Conceptual Framework
This study was guided by the CenteringPregnancy® Conceptual Framework
which incorporates Feminist Theory, the Midwifery Theory of Care, Social
Cognitive Theory, and Adult Learning Theory (Manant & Dodgson, 2011). These
theories support the relationship-based care, active learning, and self-efficacy
components of the CenteringPregnancy® program (Rising & Quimby, 2017). Selfefficacy includes how people feel, motivate themselves, and act to accomplish a
specific goal (Bandura, 1997). The components of these four theories come together
in the centering model of healthcare to make the group interactive process
supportive for participants through shared knowledge and reflection. This process is
designed to lead to successful individual outcomes during pregnancy which when
combined, may lead to a cohort of improved maternal and newborn outcomes
(Manant & Dodgson, 2011).
Methods
Institutional Review Board approval was granted by Baylor College of
Medicine (BCM) for the HIV Perinatal Study to Judy Levison, MD. Along with
obtaining IRB approval from BCM, a Data Use Agreement between BCM’s
Obstetrical & Gynecological Department and the University of Texas Health
Science Center at Houston, Cizik School of Nursing was obtained for use of the
data collected in the HIV Perinatal Study. Institutional Review Board approval
was also obtained from University of Texas Health Science Center Committee for
the Protection of Human Subjects (CPHS).
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Sample and Participant Selection
After obtaining approval from BCM and CPHS, subjects were identified
from a master list of participants of WLWH who participated in prenatal care at a
specialized clinic in an academic hospital setting in a large metropolitan, ethnically
diverse area. A power analysis using G Power 3.1.9.4 with the a priori power set at
0.80, an a priori alpha level set at .05, and with an effect size of .1 determined that a
sample size of 225 participants would be needed.
A data sheet listing inclusion and exclusion criteria was created by the
principal investigator to systematically review each of the potential subjects. Data
for a total of 489 patients receiving prenatal care during 2006 to 2018 were obtained
from the Baylor Clinical Trial Management System (CTMS). Inclusion criteria were
maternal age 18 years and older, singleton pregnancy, prenatal care at Harris Health
initiated by gestational week 30, pregnancy resulted in a live birth, and individual
one-on-one prenatal care (IC) between 2006 and 2012 or group prenatal care in the
HIV-adapted CenteringPregnancy® Program (CP-H) between 2013-2018.
Exclusion reasons included women who did not participate in group care from
2013-2018, newborns with congenital anomalies and pregnancies that ended in
fetal demise, miscarriage, or other loss, or if prenatal care began after 30 weeks
gestation. Two-hundred thirty-three charts met inclusion criteria an additional 256
were excluded (See Figure 1).
Procedure
A master list of WLWH who received prenatal care through Harris
Health/Baylor College of Medicine between 2006 and 2018 was used. All subjects
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were first determined for eligibility based on the inclusion and exclusion criteria. If
a prenatal care patient met the inclusion/exclusion criteria, they were assigned a
unique identifier for this study. Two groups were identified: individual one-on-one
care (IC) and HIV-adapted CenteringPregnancy® group (CP-H) for the study. For
both groups, the following variables were collected: maternal age, maternal
race/ethnicity, newborn gestational age, newborn birth weight, maternal viral load
recorded closest to or at delivery, month of which prenatal care began at Harris
Health, number of prenatal care appointments at Harris Health, if any infections
were present during the pregnancy, maternal smoking status, and illicit drug and/or
alcohol use during the pregnancy, diagnosis of preeclampsia, and previous preterm
birth. For the CP-H group the number of individual and group sessions were
collected.
After all of the eligible subjects’ data were entered into SPSS, the data in
each group were reviewed by the principal investigator for additional accuracy.
The review consisted of comparing every fifth subject of each group’s
information to the corresponding data in the CTMS. Six data entry errors were
found in the IC group and two data entry errors were found in the CP-H group
for an error rate of 0.286%. If a mistake was found the corrected information
was entered in SPSS from the CTMS.
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Measures
Variables that were collected for the study were:
Prenatal care
The two groups were defined by the type of prenatal care that was provided.
From 2006-2012, IC was done by two primary providers. There was no minimum or
maximum number of visits for IC. From 2013-2018, prenatal care was defined by
WLWH participating in the CP-H in 3 or more sessions. This number was selected in
order to exclude those WLWH that may have attended 1 or 2 group sessions only to
evaluate the program.
Adequacy of Prenatal Care Utilization (APNCU) Index
To calculate this index score, the month prenatal care began, the number of
prenatal care visits, and the gestational age of the newborn at birth were collected to
calculate the index score in the publicly available Adequacy of Prenatal Care Index
SAS Program (Kotelchuck, 1994b). and then transferred back into SPSS for group
analysis.
The scores for the APNCU index score start at “1” for being inadequate
based upon late initiation of prenatal care after the 4th month or less than 50% of
expected prenatal care visits attended. A score of “2” was labeled Intermediate as
prenatal care began by the 4th month of pregnancy and 50-79% of the expected
prenatal care visits are attended. The score of 3 was labeled “Adequate” for
prenatal care began by the 4th month and between 80-109% of recommended
appointments occur. The final score of “4” was considered “Adequate Plus.” This
group consisted of women who began prenatal care by the 4th month and attended

46
110% or more of recommended prenatal care visits (Kotelchuck, 1994a).
Maternal Viral Load Levels
The maternal viral load levels were listed in the CTMS as a numerical
laboratory value along with it being categorized as “undetectable.” The numerical
value was first collected. During the data collection, a list of laboratory values that
were noted to be undetectable was kept by the principle investigator. Based on the
values that were undetectable, they were then converted into a dichotomous
variable of either detectable level or an undetectable level. The dichotomous
labeling was needed to account for the differing lab values that were assigned to the
undetectable category over the 12-year span of the study. Over time, laboratory
analysis was able to detect viral levels at lower levels. The viral load level that was
included in this study was the lab value that had been recorded closest to or on the
date of delivery.
Newborn Gestational Age
The age of the newborn included both weeks and days of gestation (and
converted to a decimal number) as determined by gestational age reported by a
health care provider at delivery.
Newborn Birth Weight
The weight of the newborn that was routinely documented in the chart
within the first hours of birth in kilograms.
Analysis
SAS® (version 9.4, SAS Institute, Cary, NC). and SPSS® (version 24, SPSS
Inc., Chicago, IL) software was utilized for the data analysis. The data were initially
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entered into SPSS. The variables of month prenatal care began, the number of
prenatal care visits attended, and the gestational age of the newborn at birth were
then transferred into SAS to determine the APNCU index score. This analysis was
conducted by a senior statistician and score results were then transferred into SPSS
for analysis by the principal investigator.
Univariate analyses for potential confounding variables were completed
using Chi-Square test of Independence for presence of other infection(s), maternal
smoking status, maternal substance abuse, and diagnosis of preeclampsia. A
Fisher’s exact test for previous preterm birth was utilized due to a cell number
count of less than 5. To determine potential confounding variables in the outcome
variables analyses, the alpha level was set at .10. A higher p value was used for
this analysis as when confounding variables are unknown, a value of .10 may be
used to help identify all potential variables that may need to be controlled (Petrie &
Sabin, 2019; Thiese et al., 2016).
For the outcome variables, univariate analyses were completed. The Mann
Whitney U test was used to analyze the APNCU index score, an ordinal variable,
and a Chi-Square of Independence test was used for the maternal viral load levels, a
dichotomous variable. As both the IC newborn gestational age and newborn birth
weight groups included outliners, transformation of these variables was attempted
with no difference in distributions noted. Therefore, the original newborn
gestational age and newborn birth weight variables were used with the distribution
as a limitation. Independent sample t-tests were first utilized to examine group
differences for newborn gestational age and newborn birth weight. Mann Whitney
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U tests were also utilized due to the IC distributions. As previous preterm birth was
a potential confounding variable
for newborn gestational age and newborn birth weight, an analysis of covariance was
also used to determine if controlling for previous preterm birth influenced group
differences between the IC and CP-H groups for newborn gestational age and birth
weight.
Results
A total of 233 participants were included in this study, with 178 being in
the IC group and 55 being in the CP-H group for all analyses except for birth
weight. Due to missing birth weight data, the total subjects for the IC group
subjects was 159 and 50 subjects in the CP-H group. The IC and the CP-H groups’
demographics are summarized in Table 1. Minorities made up the majority of the
total sample with blacks being 60.9% and Hispanics being 33.0%. Both groups had
similar percentages of participants compared to the overall sample demographics.
The age range for all three groups was 18-43 years and the mean and median age
being similar for the total sample with a M= 28.42, SD= 6.14 and Mdn = 28.00.
The mean and median age for the IC group was M= 28.35, SD= 6.13 and Mdn =
27.50 and M= 28.62, SD= 6.23 and Mdn = 28.00 for the CP- H group. As age did
not follow a normal distribution, a Mann-Whitney U test was run to determine any
differences among the groups. There was no statistical difference in age between
the IC and the CP-H groups (U= 4748, z = - .339, p = .736).
Along with age and race, other potential confounding variables could have
included the presence of infection (other than HIV), maternal smoking status,
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maternal substance abuse, diagnosis of preeclampsia, and previous preterm birth.
Each of these factors are known to impact birth and newborn outcomes. Since all of
the potential confounding variables were dichotomous, a Chi-square test of
Independence was used for analysis. (See Table 2). Due to having a low sample size
for the previous preterm birth confounding variable, a Fishers Exact Test was used
and was found to be significant (p =.051) when compared to a p value of .10. A
higher p value was used for this analysis to identify any potential confounding
variable that may need to be included in further analyses. (Petrie & Sabin, 2009;
Thiese et al., 2016).
As previous preterm birth did not relate to the APNCU index score or the
maternal viral load levels, univariate analyses were completed for the APNCU
index score and the maternal viral load levels. The Mann-Whitney results for
differences in the APNCU index scores (U = 4398.500, z = -1.197, p = .231) did
not show statistical difference between the two groups. In reviewing the APNCU
index scores, the CP-H group participants did have greater “adequate” prenatal care
utilization (See Table 3) and initiation of prenatal care during the first trimester
(See Table 4) compared to the IC group participants but no significant difference
was found. For the undetectable maternal viral load levels, the Chi-Square results
were significant for differences between the IC and CP-H groups (X2 (1) = 6.543, p
= .011) with the CP-H group having a higher percentage of undetectable viral load
levels (See Table 5).
Independent t-tests and Mann Whitney U tests were first completed for both
newborn gestational age and newborn birth weight. A significant difference was

50
found with both the t-tests (See Table 6) and the Mann Whitney U test. Newborns
born to WLWH in the CP-H group had a higher gestational age compared to
newborns born to WLWH in the IC (See Table 7) (U = 3816 , z = -2.471, p = .013).
There was also a significant difference in birth weights for newborns born to
WLWH in the CP-H group compared to newborns born to WLWH in the IC group
with newborns born to WLWH in the CP-H group having higher birth weights (See
Table 8) (U = 2803.500 z = -3.14, p = .002). Further analyses also were completed
with an analysis for covariance for both newborn gestational age and newborn birth
weight. After controlling for previous preterm birth for both outcome variables, a
statistically significant difference was still found between the CP-H and IC groups
for both newborn gestational age and newborn birth weight (See Table 9 & Table
10).
Discussion
This study compared outcomes for WLWH who attended individual
prenatal care appointments and the HIV-adapted CenteringPregnancy® Program.
These two prenatal care groups were found to be similar in age, race, infections,
preeclampsia, and behaviors including smoking and substance abuse. The sample
was representative of the percentage of black WLWH in the US. The difference in
this sample is the higher percentage of Hispanic WLWH compared to general
populations of WLWH as 33% of WLWH were Hispanic in this study compared to
16% in a general population study of people living with HIV (CDC, 2019b). This
higher percentage of Hispanic WLWH identified in these prenatal groups may be
due to this southern US city having the third highest Hispanic population in the US
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(World Population Review, 2019).
Despite not finding statistical significance between the two groups for the
adequacy of prenatal care, the APNCU index scores between the IC and the CP-H
groups do provide updated information for utilization of prenatal care for WLWH.
WLWH in both groups achieved greater than 50% of the level of prenatal care that
is desired. There also was new information regarding initiation of prenatal care for
WLWH. For WLWH in the CP-H group, 72.7% began prenatal care during the
first three months (first trimester) of the pregnancy while 50.6% of IC participants
began prenatal care in the first three months. This increased adequacy of index
scores for both groups were improvements upon earlier reports for WLWH (Turner
et al., 1996) and also were improved for “adequate” and “adequate plus” compared
to WLWH in Canada who had 36.1% of WLWH receiving “adequate” care (Ng et
al., 2015).
By 2006, the guidelines for the overall treatment of HIV in WLWH included
early initiation of cART to decrease the maternal viral load and to stop maternal to
child transmission (El Beitune et al., 2004; Lynch & Johnson, 2018). The goal for
WLWH is to have an undetectable viral load during the pregnancy (ACOG, 2017).
For WLWH in the CP-H group, an increase in undetectable maternal viral loads
levels was found. For WLWH who attended HIV-adapted CenteringPregnancy®
program, 90.9% of the participants had an undetectable viral load at the viral load
closest to delivery compared to 74.7% of WLWH who attended individual one-onone prenatal care. As viral load levels are one measure of medication adherence, an
undetectable viral load may indicate an improvement with medication adherence.
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Compared to WLWH in Zahedi-Spung et al.’s study (2018) that found that 25% of
the respondents reported medication nonadherence, WLWH in the CP-H group , the
detectable viral load levels in this study was 9.1%.
Zahedi-Spung et al. (2018) also noted barriers to medication adherence
included “forgetting to take pills” and difficulty understanding that the medication
is to help both mother and baby and will not harm the baby. These two items
(reminders and education) are addressed and reinforced in the HIV-adapted
CenteringPregnancy® program (Hickerson et al., 2019) which may account for the
improved undetectable viral load levels in the intervention group.
Newborns born to WLWH in the CP-H group had a statistically significant
higher gestational age with a mean gestational age of 38.891 weeks compared to the
mean gestational age of 38.005 weeks to newborns born to WLWH in the IC group.
The longer gestational age was consistent with Tanner-Smiths et al.’s (2014)
findings of increased gestational ages among low-risk women who participated in
CenteringPregnancy group prenatal care program at five different sites in
Tennessee. This extra week may be helpful as newborns born before 39 weeks may
have increased adverse outcomes, including potential respiratory issues, and the
lengthened gestational age may be helpful to the newborn (ACOG & Society of
Maternal-Fetal Medicine, 2013).
Along with newborn gestational age, newborn birth weight was also
significantly higher for newborns born to WLWH in the CP-H group (M = 3.219 kg;
Mdn = 3.144 kg) compared to newborns born to WLWH in the IC group (M = 2.912
kg; Mdn = 2.892 kg). The increased birth weight is consistent with the increased
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gestational age finding among the CP-H group as these two outcome variables are
positively related (Tappero et al., 2016) and mirrors the current study’s data that
showed an increase in WLWH who had previous preterm birth in the IC group. The
findings also are also consistent with the Ickovics et al. (2003) study and TannerSmith et al.’s (2014) study which found that newborns born to women who had
participated in a CenteringPregnancy Program delivered newborns with increased
birth weight compared to newborns born to women who participated in individual
care.
Strengths & Limitations
Strengths of this study were that these findings provide up-to-date
quantitative information for WLWH and their newborns and that the sample size
met the a priori criteria of 225 for three of the four outcome variables.
However, there are several limitations with this study. First, this is a secondary,
retrospective data analysis and only information that had been collected in the
HIV Perinatal Study could be examined. Therefore, there are potential variables
that might have influenced the groups that were not collected such as
educational level, housing issues, domestic violence issues, and other social
determinants of health. A second limitation was that this data was collected over
12 years and that the IC group’s data were collected during a different time
frame than the CP-H group. Even though the treatment for HIV during
pregnancy was comparable during the years, potential changes related to newer
medications may need to be considered as newer medications may have
increased effect on viral load suppression and/or decreased side effects. As the
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specific medications were not collected for this study, this could not be
determined. A third limitation was that selection bias may also be a limitation
as WLWH who participated in the CP-H group self-selected if they met criteria.
A fourth limitation was that there were unequal sample sizes between the groups
and the distribution for newborn gestational age and newborn birth weight
included outliers. A final limitation was that the data had been initially entered
into the data base by multiple data collectors through the years.
Recommendations for Future Research
More research regarding WLWH and their newborns needs to be
conducted. As this was a quantitative analysis of the two groups, only certain
outcomes of the groups were studied. Therefore, to understand more about
WLWHs’ experiences in a group model of care and potentially explain more
about the quantitative results, a qualitative analysis should be conducted. Also, a
prospective study may also be considered to be able to control for other variables
that may affect outcomes that could not be collected in this retrospective analysis
study.
Conclusion
For WLWH and their newborns, prenatal care is an important part of their
pregnancy. By participating in an HIV-adapted CenteringPregnancy® group
model of care, the maternal viral loads, the newborn gestational age, and newborn
birth weight both may be improved compared to individual one-on-one prenatal
care. This study helps supports the use of the CenteringPregnancy® program
delivery method of group care and specifically for WLWH.
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Figure 1. Subjects Inclusion & Exclusion Flow Chart
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Table 1
Race/Ethnicity by Group
Group

Black

Hispanic

Caucasian

Asian/Pacific

Other

IC

60.7%

31.5%

6.7%

0.6%

0.6%

CP-H

61.8%

38.2%

0%

0%

0%

Table 2
Other Risk Factors
Risk Factor

Chi Square

p Value

Presence of Other Infection

1.26 (1, N=233)

.26

Smoking Status

2.02 (1, N=233)

.16

Substance Abuse

1.31 (1, N=233)

.25

Preeclampsia Diagnosis

2.39 (1, N=233)

.12

Table 3
Percentages of APNCU Index Scores
Group

Inadequate

Intermediate

Adequate

IC

32.6%

32.0%

CP-H

16.4%

14.0
%
14.5
%

56.4%

Adequate Plus
21.3
%
12.7
%

68
Table 4
Percentage of WLWH Initiating Prenatal Care during Trimesters
Group

1st Trimester

IC

2nd Trimester

50.6
%
72.7
%

CP-H

3rd Trimester

45.5
%
25.5
%

3.9
%
1.8
%

Table 5
Percentage of Undetectable Maternal Viral Load Levels
Group

Undetectable

IC

Detectable

74.
7%
90.
9%

CP-H

25.3
%
9.1
%

Table 6
T-test for Newborn Gestational Age & Newborn Birth Weight
df

t

p

Gestational Age

231

-2.503

.013

Birth Weight

207

-3.217

.002

Table 7
Mean & Median Gestational Age Weight
Group
IC
CP-H

M Gestational Age (weeks)
38.0
05
38.8
91

Mdn Gestational Age (weeks)
38.
571
39.
143

69
Table 8
Mean & Median Newborn Birth Weight
Group

M Birth Weight (kilograms)

Mdn Birth Weight (kilograms)

IC

2.912

2.892

CP-H

3.219

3.144

Table 9
ANCOVA for Gestational Age
df

F

p

Gestational Age

1

32.177

.014

Previous Preterm Birth

1

2.400

.123

Table 10
ANCOVA for Newborn Birth Weight
df

F

p

Birth Weight

1

3.159

.003

Previous Preterm Birth

1

1.493

.223
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A7. Research Category:
A8. Therapeutic Intent
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B. Exempt From IRB Review
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Section C: Background Information
Prior to the introduction of antiretroviral therapy the risk of transmission of HIV from mother to baby
was 25% in the United States; in the mid-1990's zidovudine (AZT) given antenatally, during labor, and
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therapy was added to most prenatal regimens and transmission further dropped to 1-2%.
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Section D: Purpose and Objectives
Although some data regarding the demographics and details of patient care have been recorded by
Harris County

73

Hospital District, no systematic review designed by clinicians has been done. Our goal is to create a data base
and to use the information gleaned for quality assurance purposes and to direct future research.
For each of the clients enrolled from 2006 to 2018, we will review clinic and hospital charts to obtain
the targeted information.
The following items will be evaluated:
-Source of referral (BTGH, outlying clinics) -Zip code of patient -Age -Race/ethnicity Gravidity/parity -Date of
diagnosis
-Diagnosed during pregnancy: Past, Current -In care during the 6 months prior to pregnancy -Partner
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Section E: Protocol Risks/Subjects
E1. Risk Category
Category 1: Research not involving greater than minimum risk.
E2. Subjects
Gender: Female
Age:
Adolescent (13-17 yrs), Adult (18-64 yrs), Fetus
Ethnicity:
All Ethnicities
Primary Language:
Groups to be recruited will include:
Asymptomatic patients with chronic conditions, healthy
Which if any of the following vulnerable populations will be recruited as subjects?
Vulnerable populations require special protections. How will you obtain informed consent, protect subject
confidentiality, and prevent undue coercion?
Not applicable. This is a chart review.
E3. Pregnant woman/fetus
Will pregnant women and/or fetuses (as described in 45 CFR 46 Subpart B) be enrolled in the research?
No
E4. Neonates
Will neonates of uncertain viability or nonviable neonates (as described in 45 CFR 46 Subpart B) be enrolled in
the research?

74
No
E5 Children
Will children be enrolled in the research? No
Section F: Design/Procedure
F1 Design
Select one category that most adequately describes your research:
a) Chart/scan/record review
Discuss the research design including but not limited to such issues as: probability of group
assignment, potential for subject to be randomized to placebo group, use of control subjects, etc.
Retrospective chart review: Charts from 2006 through June 30, 2018 will be reviewed.
Inclusion Criteria
The subject/research population will include all women enrolled in the Harris County Hospital District
Women's Program and UCSF's prenatal program providing obstetrical care for HIV-positive women.
Includes those who transfer care or have a miscarriage. The control group will be comprised of HIVnegative women obtaining obstetrical care at the Harris County Hospital District Vallbona Health
Center. This includes patients who transfer care or have a miscarriage.
Exclusion Criteria
Non-pregnant women
F2 Procedure
NA
Section G: Sample Size/Data Analysis
G1. Sample Size
How many subjects (or specimens, or charts) will be used in this study?
Local: 1000

Worldwide: 1000

Please indicate why you chose the sample size proposed:
There have been 486 women enrolled in the Harris County Hospital District Women's Program at
Northwest Clinic since 2000. We will focus on women who delivered between 2006 and June 30,
2018, since their records are available electronically.
G2. Data Analysis
Provide a description of your plan for data analysis. State the types of comparisons you plan (e.g.
comparison of means, comparison of proportions, regressions, analysis of variance). Which is the
PRIMARY comparison/analysis? How will the analyses proposed relate to the primary purposes of
your study?
This study is primarily a descriptive study of the outcomes of this program for quality improvement
and research purposes. However, these outcomes will also be compared to a control population in
order to determine statistical and clinical significance which in turn can lead to quality improvement
and spawn further research. Because only three women have delivered an HIV-infected child,
hypothesis testing of the correlates of avoiding vertical transmission cannot be done. We will instead
describe our patient population characteristics, HIV treatment characteristics, and
obstetric/gynecologic care characteristics. Any statistical methods to compare such characteristics
will use the chi- square test for categorical data, the t-test or ANOVA for continuous data that is
normally distributed, and the Wilcoxon or Kruskal-Wallis test for non-parametric data. Standard
multivariate regression techniques may also be used
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Section H: Potential Risks/Discomforts
H1.Potential Risks/Discomforts
Describe and assess any potential risks/discomforts; (physical, psychological, social, legal, or other)
and assess the likelihood and seriousness of such risks:
Since the subjects can be identified by medical record number, there is a risk of loss of
confidentiality. However, records will be kept in a locked file cabinet to reduce this risk.
H2. Data and safety monitoring plan
Do the study activities impart greater than minimal risk to subjects?
No
H3. Coordination of information among sites for multi-site research
Is the BCM Principal Investigator acting as the SPONSOR-INVESTIGATOR for this multi-site research?
No or Not Applicable
Is BCM the COORDINATING CENTER for this multi-site research?
No or Not Applicable
Section I: Potential Benefits
Describe potential benefit(s) to be gained by the individual subject as a result of participating in the planned
work.
None.
Describe potential benefit(s) to society of the planned work.
The study will help us to focus our future efforts to improve our program.
1) Demographic information, e.g. zip code, will tell us which parts of the city we should be targeting with
preventive messages and where HIV services are perhaps needed.
2) Partner notification: We need to know the baseline number of clients who disclose their HIV status to
sexual partners. Thereafter, we might develop an intervention strategy and study whether the disclosure
rate subsequently increases.
3) Time of diagnosis: The percentage diagnosed via routine prenatal screening will support or refute
advantages of routine prenatal screening (may support the Texas approach as a model for other states).
4) Correlation of viral load (VL) and CD4 counts with obstetric complications
5) Viral loads at time of delivery: if the percentage of women that do not achieve an undetectable VL by the
time of delivery is high, then we might need to repeat VLs more frequently to provide time before delivery
for more intensive counseling about adherence.
6) Gestational age at delivery: Is the incidence of prematurity greater than in the general population?
Is preterm delivery associated with lower CD4s, particular drugs, or other HIV-related problems?
7) Postpartum care: What fraction of women return for postpartum care? How many women stop
antiretroviral (ARV) therapy because they were instructed to (CD4 prior to treatment <350)? How many stop
ARV therapy by their own choice (against medical advice)?
8) Will assess how rapidly viral loads decrease after initiation of antiretroviral therapy. The results may
influence national guidelines for who is advised to have a Cesarean and who may have a vaginal delivery. The
current recommendation for women who present at 36 weeks gestation with HIV and not on therapy is for
Cesarean section at
38 weeks. If we can show that viral loads below a certain level can be reduced to less than 1000 in 2
weeks or less, then more women may be allowed to safely deliver vaginally.
Do anticipated benefits outweigh potential risks? Discuss the risk-to-benefit ratio.
Yes. We may significantly improve our program. The data base may suggest trends that warrant further
research. There is no risk to the clients. There is no change from the past in risk to benefit ratio.
Section J: Consent Procedures
J1. Waiver of Consent
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Will any portion of this research require a waiver of consent and authorization?
Yes\
Please describe the portion of the research for which a waiver is required. (Example: chart review to
determine subject eligibility)
Chart review to look at demographics and clinical dataExplain why the research and the use or
disclosure of protected health information involves no more than minimal risk(including privacy risks)
to the individuals.
This is a retrospective chart review to create a database. PHI will be de-identified and kept in a
secure BCM database.
Explain why the waiver will not adversely affect the privacy rights and the welfare of the research
subjects.This is a retrospective chart review to create a database. PHI will be de-identified and kept in
a secure BCM database.
Explain why the research could not practicably be conducted without the waiver and could not
practicably be conducted without access to and use of the protected health information.Since this is a
retrospective review, we no longer have contact information for many clients. We cannot access the
necessary information without reviewing charts.
Describe how an adequate plan exists in order to protect identifiers from improper use and
disclosure.We are using a carefully protected database program created by the Institute for Clinical
and Translational Research
(ICTR) at BCM.
Describe how an adequate plan exists in order to destroy identifiers at the earliest opportunity
consistent with conduct of the research, unless there is a health or research justification for retaining
the identifiers or such retention is otherwise required by law.The list of patients is in a secure Harris
Health database which can only be accessed by protocol investigators.
Describe how adequate written assurances exist in order to ensure that the PHI will not be reused or
disclosed to (shared with) any other person or entity, except as required by law, for authorized
oversight of the research study, or for other research for which the use or disclosure of the PHI would
be permitted under the Privacy Rule.All investigators have completed education on human subjects
protection and understand that information is not to be shared.
Information from health records such as diagnoses, progress notes, medications, lab or radiology
findings, etc.
Yes
Specific information concerning alcohol abuse: Yes
Specific information concerning drug abuse: Yes
Specific information concerning sickle cell anemia: Yes
Specific information concerning HIV: Yes
Specific information concerning psychiatry notes: Yes
Demographic information (name, D.O.B., age, gender, race, etc.): Yes
Full Social Security #: No
Partial Social Security # (Last four digits): No
Billing or financial records: No
Photographs, videotapes, and/or audiotapes of you:
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No
Other:
No
Will additional pertinent information be provided to subjects after participation?
No
If No, explain why providing subjects additional pertinent information after participation is not appropriate.
Since this is a retrospective chart review covering a >5 year time period, we no longer have contact
information for many clients.
J1a. Waiver of requirement for written documentation of Consent
Will this research require a waiver of the requirement for written documentation of informed consent?
Yes
Explain how the only record linking the participant and the research would be the consent document, and
how the principal risk would be potential harm resulting from a breach of confidentiality, and how each
participant will be asked whether he or she wants documentation linking the participant with the research
and their wishes will govern.
Consent is not relevant to this study as outlined above.
J2. Consent Procedures
Who will recruit subjects for this study?
PI
Describe how research population will be identified, recruitment procedures, any waiting period between
informing the prospective participant and obtaining consent, steps taken to minimize the possibility of
coercion or undue influence and consent procedures in detail.
Harris County Hospital District has maintained a list of clients who have been enrolled in prenatal care through
the Women's Program. The electronic charts of clients identified by the HHS as being enrolled in the Women's
Program will be electronically viewed at Northwest Health Center on their system. This will also include
electronic birth outcome records for deliveries that occur at Ben Taub General Hospital. Occasionally, hard copy
charts may be pulled at the Northwest Clinic to obtain information for this database that may not be included in
the HHS electronic medical record. All electronic medical record and hard copy record data collection will occur
at Northwest Health Clinic.
Are foreign language consent forms required for this protocol?
No
J3. Privacy and Intrusiveness
Will the research involve observation or intrusion in situations where the subjects would normally have an
expectation of privacy?
No
J4. Children
Will children be enrolled in the research?
No
J5. Neonates
Will non-viable neonates or neonates of uncertain viability be involved in research?
No
J6. Consent Capacity - Adults who lack capacity
Will Adult subjects who lack the capacity to give informed consent be enrolled in the research?
No
J7. Prisoners
Will Prisoners be enrolled in the research?
No
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Section K: Research Related Health Information and Confidentiality
Will research data include identifiable subject information?
No
Information from health records such as diagnoses, progress notes, medications, lab or radiology
findings, etc.
Yes
Specific information concerning alcohol abuse: Yes
Specific information concerning drug abuse: Yes
Specific information concerning sickle cell anemia: Yes
Specific information concerning HIV: Yes
Specific information concerning psychiatry notes: Yes
Demographic information (name, D.O.B., age, gender, race, etc.): Yes
Full Social Security #: No
Partial Social Security # (Last four digits): No
Billing or financial records: No
Photographs, videotapes, and/or audiotapes of you: No
Other: No
At what institution will the physical research data be kept?
The data will be entered into a secure BCM database created by the Institute for Clinical and
Translational Research at
BCM.
How will such physical research data be secured?
Information will go directly into the secure online database.
At what institution will the electronic research data be kept?
BCM
Such electronic research data will be secured via BCM IT Services- provided secured network
storage of electronic research data (Non-Portable devices only):
Yes
Such electronic research data will be secured via Other: No
Will there be anyone besides the PI, the study staff, the IRB and the sponsor, who will have access to
identifiable research data?
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No
Please describe the methods of transmission of any research data
(including PHI sponsors and/or collaborators).
Co-investigators must enter secure online database.
Will you obtain a Certificate of Confidentiality for this study?
No
Please further discuss any potential confidentiality issues related to this study.
None
Section L: Cost/Payment
Delineate clinical procedures from research procedures. Will subject's insurance (or subject) be responsible for
research related costs? If so state for which items subject's insurance (or subject) will be responsible (surgery,
device, drugs, etc). If appropriate, discuss the availability of financial counseling.
NA
If subjects will be paid (money, gift certificates, coupons, etc.) to participate in this research project, please note
the total dollar amount (or dollar value amount) and distribution plan (one payment, pro-rated payment, paid
upon completion, etc) of the payment.
Dollar Amount:
0
Distribution Plan: NA
Section M: Genetics
How would you classify your genetic study?
Discuss the potential for psychological, social, and/or physical harm subsequent to participation in this research.
Please discuss, considering the following areas: risks to privacy, confidentiality, insurability, employability,
immigration status, paternity status, educational opportunities, or social stigma.
Will subjects be offered any type of genetic education or counseling, and if so, who will provide the education or
counseling and under what conditions will it be provided? If there is the possibility that a family's pedigree will be
presented or published, please describe how you will protect family member's confidentiality?

Section N: Sample Collection
None
Section O: Drug Studies
Does the research involve the use of ANY drug* or biologic? (*A drug is defined as any substance that is used
to elicit a pharmacologic or physiologic response whether it is for treatment or diagnostic purposes)
No

Does the research involve the use of ANY gene transfer agent for human gene transfer research?
No
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O1. Current Drugs
Is this study placebo-controlled?

No
Will the research involve a radioactive drug that is not approved by the FDA?
No

Section P: Device Studies
Does this research study involve the use of ANY device?
No

Section Q. Consent Form(s)
None

Section R: Advertisements
None
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DATA USE AGREEMENT
This Data Use Agreement ("Agreement") is made and entered into as of this 12th_ day of _July, 2019_ by and
between BAYLOR COLLEGE OF MEDICINE ("BAYLOR") with principal offices located at One Baylor Plaza,
Houston, Texas 77030, and, UTHealth Cizik School of Nursing ("RECIPIENT") with principal offices located at
6901 Bertner Avenue, Houston, Texas, 77030, individually, a "Party," and collectively, the "Parties." The effective
date of this Agreement is the date of the last signature.
WHEREAS, BAYLOR may Disclose or make available to RECIPIENT certain Protected Health
Information ("PHI") in the form of a Limited Data Set, as defined below, and RECIPIENT may receive, Use,
Disclose, transmit, maintain or create from the Limited Data Set certain information for purposes of research,
public health, or health care operations as provided below; and
WHEREAS, BAYLOR, a Covered Entity as defined by the HIPAA Rules, and RECIPIENT are committed
to comply with the Privacy, Security, Breach Notification, and Enforcement Rules at 45 C.P.R. Parts 160 and 164 of the
Health Insurance Portability and Accountability Act of 1996, known collectively as the HIPAA Rules, and the Health
Information Technology for Economic and Clinical Health Act (HITECH) amendments to the HIPAA Rules; and
WHEREAS, BAYLOR is required to obtain assurances from RECIPIENT that RECIPIENT will only Use
or Disclose PHI as permitted by this Agreement, and;
WHEREAS, the Parties enter into this Agreement as a condition to BAYLOR furnishing the Limited
Data Set to RECIPIENT once RECIPIENT has provided assurances about its Use and Disclosure of the Limited Data
Set.
NOW, THEREFORE, in consideration of the mutual covenants and representations contained herein, the
Parties agree as follows:
A.

DEFINITIONS

Capitalized terms used but not otherwise defined in this Agreement shall have the same meaning as those terms in the
HIPAA Rules.
1. Limited Data Set of direct identifiers shall have the same meaning as the term "limited data set" in 45
CPR 164.514(e) of the Privacy Rule. Unless otherwise required by the HIPAA Rules, the term "Limited
Data Set" shall include only the following direct identifiers of the Individual or of relatives, employers or
household members of the Individual:
a)
b)
c)
d)
e)

Dates of treatment, admission, discharge
Birth date, date of death
Age (including age 90 or over)
Geographic subdivisions such as state, country, town, city, precinct, and zip code
Unique codes or identifiers that are not direct identifiers or replicates of a part of direct identifiers.

2. Direct Identifiers, other than those of a Limited Data Set, may not be disclosed with this Agreement.
The following direct identifiers of the Individual or of relatives, employers, or household members of the
Individual are as follows:
a) Nameb) All geographic subdivisions smaller than a State, including street address, city,

county, precinct, zip code, and their equivalent geographic codes, except for the initial three
digits of a zip code if, according to the current publicly available data from the Bureau of the
Census: (l)The geographic unit formed by combining all zip codes with the same three initial
digits contains more than 20,000 people; and (2) The initial three digits of a zip code for all such
geographic units containing 20,000 or fewer people is changed to 000.
c) All elements of dates (except year) for dates directly related to an individual, including birth
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date, admission date, discharge date, date of death; and all ages over 89 and all elements
of dates (including year) indicative of such age, except that such ages and elements may be
aggregated into a single category of age 90 or older
d) Telephone numbers, fax numbers
e) Electronic mail addresses
f) Social Security numbers, medical record numbers, health plan beneficiary
numbers g) Account numbers, Certificate/license numbers
h) Vehicle identifiers and serial numbers, including license plate
numbers i) Device identifiers and serial numbers
j) Web Universal Resource Locators (URLs)
k) Internet Protocol (IP) address numbers
I) Biometric identifiers, including finger and voice prints
m) Full face photographic images and any comparable image
n) Any other unique identifying number, characteristic, or code, except as permitted as a means
of record identification to allow information de-identified to be re-identified.
3. Commercial purposes: The sale, lease, license, or other transfer of the Limited Data Set to a forprofit organization (other than RECIPIENT) and shall also include uses of the Limited Data Set by
any organization, including RECIPIENT, to perform contract research, to produce or manufacture
products for general sale, or to conduct research activities that result in any sale, lease, license, or
transfer of the Limited Data Set to a for-profit organization.
B. SCOPE AND PURPOSE
1. This Agreement sets forth the terms and conditions pursuant to which BAYLOR will Disclose
certain
PHI in the form of a Limited Data Set to RECIPIENT.
2. Except as otherwise specified by this Agreement, RECIPIENT may make all Uses and Disclosures
of the Limited Data Set necessary for the designated research, public health, or health care
operations as described herein: HIV-adapted CenteringPregnancy® Program Outcomes for Women
Living with HN and their Newborns
{Permitted Data Use"). If the Permitted Data Use is for research, provide the protocol number:
HN
Perinatal Database, Protocol Number: H-18412
3. Any and all other studies or uses of the Limited Data Set are expressly prohibited and may not
be pursued by the RECIPIENT, any member of the RECIPIENT'S staff or any agent or
subcontractor of the RECIPIENT without written approval of BAYLOR.
4. The Limited Data Set shall not be used for any commercial purposes.
5. In addition to the RECIPIENT, there are no other individuals, or classes of individuals, who
are permitted to use or receive the PHI contained within the Limited Data Set for the Permitted
Data Use.

6. The Limited Data Set to be provided by BAYLOR to the RECIPIENT per the Data Use Agreement
for
the Permitted Data Use consists of the following direct identifiers: Dates of prenatal care
appointments (labeled as traditional or Centering), age, and Clinical Trials Management System
Patient Accession Number
7. Additional data to be provided with the Limited Data Set that are not direct identifiers are as
follows: race, education level, presence of infection other than HIV during pregnancy, smoking
status, previous preterm birth, diagnosis of preeclampsia, gestational age of newborn, plasma
RNA level (viral load) prior to delivery, live birth, fetal demise, miscarriage, single or multiple
pregnancy, and newborn birth weight
8. Describe in detail how RECIPIENT will secure and protect the Limited Data Set including but
not limited to a description of the security of any databases to be used and how the Limited Data
Set will be transmitted, if applicable, and stored: Data will be stored on a secure network at
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C. OBLIGATIONS AND ACTIVITIES OF RECIPIENT
1. RECIPIENT agrees to the following:
a) To not Use or further Disclose the Limited Data Set for any purpose other than as permitted by
this
Data Use Agreement or as Required by Law;
b) To use appropriate data security measures and other safeguards to prevent inappropriate Use
or
Disclosure of the Limited Data Set other than as provided by this Agreement;
c) To notify BAYLOR, in writing, of any Use or Disclosure of the Limited Data Set not provided
for by this Agreement of which RECIPIENT becomes aware, including without limitation,
any Disclosure of PHI to an unauthorized employee, agent or subcontractor of the RECIPIENT,
within ten (10) days of its discovery;
d) To ensure that any agent and/or subcontractor of RECIPIENT to whom it provides the
Limited Data Set agrees, in writing, to the same standards, restrictions and conditions that
apply through this Agreement to the RECIPIENT.
e)
To not identify the information contained in the Limited Data Set or contact the
Individual/s.
f) To not create, receive, maintain, transmit, Use or Disclose the Limited Data Set outside of
the
United States.
2. This Data Use Agreement does not authorize the RECIPIENT to Use or Disclose the Limited Data
Set for the Permitted Data Use in a manner that would violate the requirements of the HIPAA Rules
if done by BAYLOR.
3. RECIPIENT will indemnify, defend and hold harmless BAYLOR and any of BAYLOR'S
affiliates, and their respective trustees, officers, directors, employees and agents ("Indemnitees")
from and against any claim, cause of action, liability, damage, cost or expense (including, without
limitation, reasonable attorney's fees and court costs) arising out of or in connection with any
unauthorized or prohibited Use or Disclosure of the Limited Data Set or any other breach of this
Agreement by RECIPIENT or any subcontractor, agent or person under RECIPIENT'S control.

85
4.

RECIPIENT understands that violations of the terms of this Agreement by RECIPIENT
may be considered violations of the federal HIPAA Rules.

D. TRANSFER OF DATA
After execution of this Agreement, BAYLOR shall deliver the Limited Data Set and any additional
data that are not direct identifiers as provided in Section B.7. to the RECIPIENT in the following
secure manner: Recipient will be extracting data from Baylor Clinical Trial Management System as
she is an approved user with a current password to the system.
RECIPIENT:

Name: Dr. Diane Wardell
Title:
UTHealth Cizik School ofNursing
Address:
E-mail address: Diane.Wardell@uth.tmc.edu
Phone:
713-500-2056, SON-589
Other:

With a copy to: Name : Jodi H Behr
Title:
PhD Candidate!UTHealth Cizik School ofNursing;
Research Assistant Baylor
College of Medicine Ob/Gyn Department
Address:
E-mail address: Jodi.h.behr@uth.tmc.edu; Jodi.behr@bcm.edu
Phone:
502-759-1333
Other:

E.
TERM
TERMINATION

AND

1. This Agreement shall terminate when all of the Limited Data Set, including copies or replicas,
provided by BAYLOR to RECIPIENT for the Permitted Data Use is destroyed, as evidenced
by a Certificate of Destruction, or securely returned to BAYLOR. If it is not feasible to return
or destroy the Limited Data Set, appropriate data protection and safeguards are extended to the
Limited Data Set in accordance with the requirements of the HIPAA Rules and this Agreement
for as long as the Limited Data Set remains in possession by the RECIPIENT.
2. Destruction of the Limited Data Set must be in accordance with industry standards and
processes for ensuring that reconstruction, re-use, and/or re-disclosure of the Limited Data Set
is prevented after destruction using a method effective for the media in which the Limited Data
Set is contained.
3. Either Party may terminate this Agreement for a material breach by the other Party, if such
breach is not cured to the satisfaction of the non-breaching Party within thirty (30) days after
the non-breaching Party gives written notice of the breach to the breaching Party

F. MISCELLANEOUS
1. A reference in this Agreement to a section in the HIPAA Rules means the section as amended
or as renumbered.
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2.

The parties agree to take such action as is necessary to amend this Agreement from time to
time as is necessary for Covered Entity to comply with the requirements of the HIPAA Rules.
3. The respective obligations of RECIPIENT under Section C of this Agreement shall survive
termination of this Agreement.
4. Any ambiguity in this Agreement shall be resolved to permit BAYLOR to comply with the
HIPAA Rules.
5. There are no intended third party beneficiaries to this Agreement. Without in any way limiting
the foregoing, it is the Parties' specific intent that nothing contained in this Agreement gives
rise to any right or cause of action, contractual or otherwise, in or on behalf of the individuals
whose PHI is Used or Disclosed pursuant to this Agreement.
6. Nothing in this Agreement shall be construed to create: (i) a partnership, joint venture, or
other joint business relationship between the Parties or any of their affiliates; (ii) any fiduciary
duty owed by one Party to another Party or any of its affiliates; or (iii) an agency or employment
relationship between the Parties or any of their affiliates.
7. Failure or delay on the part of either Party to exercise any right, power, privilege or remedy
hereunder shall not constitute a waiver thereof. No provision of this Agreement may be waived
except by an agreement in writing signed by the waiving party. A waiver of any term or
provision shall not be construed as a waiver of any other term or provision.
8. The persons signing below have the right and authority to execute this Agreement and no
further approvals are necessary to create a binding agreement.
9. The provisions of this Agreement shall be severable and, if any provision of this Agreement
shall be held or declared to be illegal, invalid or unenforceable, the remainder of this Agreement
shall continue in full force and effect as though such illegal, invalid or unenforceable provision
had not been contained herein.
I 0. The descriptive headings of the articles, sections, subsections, exhibits and schedules of this
Agreement are inserted for convenience only, do not constitute a part of this Agreement, and
shall not affect in any way the meaning or interpretation of this Agreement.
11. In the event of any conflict between the terms and conditions stated within this Agreement
and those contained within any other agreement or understanding between the parties, written,
oral or implied, the terms of this Agreement shall govern. Without limiting the foregoing, no
provision of any other agreement or understanding between the parties limiting the liability of
RECIPIENT to BAYLOR shall apply to the breach of any covenant in this Agreement by
RECIPIENT.
12. This Agreement shall be construed in accordance with and governed by the laws of the State
of Texas or jurisdiction of BAYLOR without regard to applicable conflict of laws principles.
Any suit, action or proceeding against either Party with respect to this Agreement shall be
brought in the state or federal courts located in Harris County, Texas, and the other Party hereby
submits to the non-exclusive jurisdiction of such courts for the purpose of any such suit, action
or proceeding.
13. Any notices pertaining to this Agreement shall be given in writing and shall be deemed duly
given when personally delivered to a Party or a Party's authorized representative as listed
below or sent by means of a reputable overnight carrier, or sent by means of certified mail,
return receipt requested,
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postage prepaid. A notice sent by certified mail shall be deemed giYcn on the date of receipt or refusal
o( retelpl All notices shall be addressed to the appropriate Pany liS follows:
lfto BAYLOR
Baylor College of Medicine Chief Compliance Officer One Baylor PlRZB MSBCM265
Houston, Texas 77030

I 4. This Agreement is binding upon and inures to the benefit of the Parties hereto and
their respective successors 1111d permitted assigns. However, neither Pany may
BSSilltl any of its rights or delegale any of its obligatims under this Agreement
without the prior wrinen consent of the other Party, which OO!ISCI\t sllaiii\OI be
onably withheld or delayed. Notwithstanding any provisions to the oontruy,
however, BAYLOR retains the right to assign or delegate any of its rights or
obligations hereunder to any of illl wholly owned subsidiaries, affiliates or sucussor
companies. Assignments lllldc in violation of this provision tR null and void.
15. This Agreement, together with all exhibits, schedules, riders, IUid amendments, if
applicable, which arc IUlly completed and signed by authorized persons on behalf of
both Parties from time to time while this Agreement is in effca, oonstitulell the entire
Agreement between the Parties hcn:to with respect to the subjeet mancr f and
supersedes all previous writlen or oral undeBW dings. agrc:cments,
negotiations, commitmmts, and any other writing and communication by or
between the Panics with respect to the subject mllller hetco[ In tile event of lllly
inconsistencies between any provisions ofthis AgR>cmentin BIIY provisions of the
exhibits, sc:hcdulcs. riders, and Amendment, the provisions of this Ag.rtc.11enl shall
COIIIJ'OI••

16. An electronic c:opy or fBCSimilc of a signature hereto will be binding upon the
signatory as if it were an original si .
IN WITNESS WHEREOF, the parties have executed this Agreement effective upon the
Effective Date set forth aboYe.

es shall be addressed to the appropriate Pany

liS

follows:
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Date:

----- ------------

Stamped Approval Space

---------------
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Data Management and Codebook
1.

Introduction
The purpose of this document is to provide a step-by-step guide and serve as a
reference for the data collection process.

2. Assessing eligibility criteria
A master list of subjects that were provided care through Harris Health and Baylor
College of Medicine will be obtained from Judy Levison, MD, MPH. The master
list will contain names and medical record numbers. If inclusion criteria are met
and no
exclusion criteria apply, the name and the medical record number will be used to
access the CTMS system record for the subject.
Once the subject is included, a study identification number will be assigned in the
principal investigator’s database. A four-digit identifier will be assigned to each
subject. The first two digits will be the year the subject started prenatal care and
the last two
digits will be a consecutive running list of numbers.
3. Study Personnel
Study personnel will enter the following codes found in the Variable Codebook
into the data worksheet.
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Variable

Definition

Age

Age of mother Years
at first prenatal
care visit
Race of mother None

Race

Units of
Variables

Infections

Presence of
infection(s)
other than HIV

None

Mother’s
smoking status

Mother’s
smoking status
during
pregnancy

None

Mother’s other
substance
abuse

Mother’s use
of other
substances by
self-reported
information

None

Previous
preterm birth

A birth that
occurred prior
to 37 weeks
gestation
A single or
multiple
newborn
A congenital
anomaly

None

A pregnancy
that resulted in

None

Single/Multiple
Birth
Congenital
anomaly of the
newborn
Fetal demise

None
None

Coding for
Variable in
SPSS
Numerical
value

Data Source in
BCM CTMS

1 Caucasian
2 Black
3 Hispanic
4 Asian/Pacific
Islander
5 Native
American
6 Other
0 No presence
of other
infection
1 Presence of
other infection
0 Did not
smoke during
pregnancy
1 Did smoke
during
pregnancy
0 Did not use
other
substances
during
pregnancy
1 Did use other
substances
during
pregnancy
0 Non previous
preterm birth
1 Previous
preterm birth
0 Single birth
1 multiple birth

Demographics

0 No
congenital
anomaly
1 congenital
anomaly
0 No fetal
demise

Pregnancy
Complications

Demographics
screen

Pregnancy
Complications

Substance
abuse screen

Substance
abuse screen

Pregnancy
detail screen
Newborn
screen

Pregnancy
Complications
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a fetal demise
Miscarriage
Type of
prenatal care

A pregnancy
that ended in
miscarriage
Care provided
to the mother
during
pregnancy:

1 Fetal demise
None

0 No
miscarriage
1 Miscarriage
0 Traditional
one-on-one
care
1 group
prenatal care
(Centering)

Pregnancy
Complications

None

1 Inadequate
2 Intermediate
3 Adequate
4 Adequate
Plus

Estimated
gestational age
at entry into
program:
Pregnancy
details screen

Months

NA

Pregnancy
details screen

Visits

NA

Number of
visits screens

Weeks of
gestation at
birth
None

NA

Baby Outcome
Screen

0 Detectable
maternal HIV
RNA levels
1 Undetectable
maternal
plasma HIV
RNA levels

Lab screen

Numerical
value

Baby outcome
screen

Numerical
value

Baby outcome
screen

None

Two different
models
provided
One on one
care or group
prenatal care
Adequacy of
Index score is
prenatal care:
derived from
Adequacy of
To calculate the Prenatal Care
index score the Index.
following data
is needed:
1.Gestational
month prenatal
care began at
Harris Health
(MPCBBC)
2.Number of
visits
(NPCVBC)
3. Gestational
age
(GAGEBC)
Maternal
plasma HIV
RNA levels

Newborn
gestational age
Newborn birth
weight

The month of
the pregnancy
that prenatal
care began at
Harris Health
Number of
prenatal care
visits at Harris
Health
Newborn
gestational age

Number of
HIV plasma
RNA cells in
maternal blood
in last
specimen
collected prior
to delivery
Gestational age Weeks & days
of newborn at
delivery in
weeks & days
Birth weight of Kilograms
newborn

Visits screen
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HCA Healthcare Houston West
Houston, TX
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97
Home Hospital
Lafayette,
IN
NICU Staff Nurse

03/1995 – 08/1996

Pediatric Nursing Specialists
Indianapolis,
IN
Home care nurse for
technology dependent
children

10/1994 – 03/1995
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Stewart, D. L. & Behr, J. H. (2012). Pain and stress in the neonate. Journal
of the
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PRESENTATIONS:
Poster Sessions
The Parent Involvement Continuum: The Importance of Achieving Parental
Presence, Participation, and Engagement in the NICU, National Association of
Neonatal Nurses Annual Conference, Poster Presentation, 07/2019
Predictors of Suicide and Weapon Carrying Among High School Students, The
University of Texas Health Science Center at Houston Cizik School of Nursing
Research Day, 04/2018
The Use of a Double Barrier Hydrocolloid Dressing to Prevent Skin Breakdown in
Very Low Birth Weight Neonates (VLBWs) on High Flow Nasal Cannula,
National Association of Neonatal Nurses Annual Conference & Research!
Louisville Nursing Symposium, Poster Presentation, 10/2013
An Evidence-based Approach to Preventing Hypothermia in Very Low Birth Weight
Babies, Poster Presentation, Research! Louisville Nursing Symposium, 09/2012
Promoting Evidence-Based Skin Care Practices through Skin Care Rounds, National
Association of Neonatal Nurses Annual Conference, Poster Presentation, October
2011
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of Neonatal Nurses Annual Conference & Research! Louisville Nursing
Symposium, Poster Presentation, 10/2010
Achieving Staff Compliance with Pulse Oximetry Alarm Limits and Saturation
Goals for Neonates 32 Weeks and Less, National Association of Neonatal Nurses
Annual Conference & Research! Louisville Nursing Symposium, Poster
Presentation, 10/ 2010
Promoting Evidence-Based Practice Through a Virtual Journal Club, National
Association of Neonatal Nurses Annual Conference & Research! Louisville
Nursing Symposium, Poster Presentation, 10/2010
Collaboration Within the CA-BSI Collaborative: National Association of Children’s
Hospitals and Related Institutions Annual Conference, Poster Presentation, 10/2008
Podium & Invitation Presentations
HIV-adapted CenteringPregnancy® Program Outcomes for Women Living with
HIV and their Newborns, Robert Wood Johnson Future of Nursing Scholar Summer
Institute,
07/2018 & 07/2019
The Use of Smartphones by Nurses in the Clinical Setting, Norton Healthcare Chief
Nursing Officers Meeting, 03/2016
Norton Healthcare Professional Nursing Practice, Norton Healthcare Institute for
Nursing, 07/2015- 06/2016
Evidence-based Practice Workshop, Norton Healthcare Institute for Nursing,
09/2015
Neonatal and Pediatric Pain: Babies and Kids Are Different, Kosair Children’s
Hospital
Nursing Grand Rounds, 07/2015
The Johns Hopkins Evidence-Based Practice Model, Norton Healthcare Nurses Are
Leaders Nursing Symposium, 05/2014
The Johns Hopkins Evidence-Based Practice Model, Norton Healthcare Institute for
Nursing Evidence-Based Practice Mentor Workshop, 04/2014
Clinical Practice Guidelines, Norton Healthcare Institute for Nursing EvidenceBased
Practice Mentor Workshop, 04/2014

100
NIRS and Nursing Care: Can Using Near-Infrared Spectroscopy Enhance Nursing
Care in the NICU? National Association of Neonatal Nurses Annual Conference,
Specialty Session Presentation, 10/2013
New Innovations in the Care of the Neonate, University of Louisville School of
Medicine
Pediatric Grand Rounds, 04/2013
Updates on Skin Care in the Neonatal Intensive Care Unit, Kosair Children’s
Hospital
Nursing Grand Rounds, 08/2013
Lessons Learned through the IRB Journey, Podium Presentation, Research!
Louisville
Nursing Symposium, 12/2012
The OWLs (Oxygen with Love) Have It: Association of Women’s Health, Obstetric,
and
Neonatal Nurses Annual Conference, Specialty Session Presentation, 09/2010
AWARDS & RECOGNITION
2017 – 2020

Robert Wood Johnson Foundation Future of Nursing Scholar

2016
Internship

Nursing Organization Alliance Nurse in Washington
Scholarship Recipient

2014

Norton Healthcare Evidence-Based Practice Nurse of the Year

1993

Purdue University’s Helen R. Johnson Senior Nursing
Undergraduate Scholarship

